In addition, MDM2 has been shown to be abnormally upregulated due to gene amplification, increased transcription, and enhanced translation, leading to enhanced degradation and reduction of P53 activity in some human tumors (Konopleva et al., 2020)and therefore, many drugs/compounds have been developed for reactivation of P53 gene by inhibiting MDM2 interaction with P53 in order to treat cancer (Gupta et al., 2019). This evidence concerns the gene MDM2 and cancer.